Hikma Pharmaceuticals PLC (HIK) — Working Capital to Net Assets Ratio
Hikma Pharmaceuticals PLC (HIK) has a Working Capital to Net Assets ratio of 19.6% as of June 2025. Working capital of GBX501.00 Million (current assets of GBX2.56 Billion minus current liabilities of GBX2.06 Billion) is measured against net assets of GBX2.55 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See HIK defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Hikma Pharmaceuticals PLC Working Capital to Net Assets (2002–2024)
This chart shows how Hikma Pharmaceuticals PLC's Working Capital to Net Assets ratio has evolved across 23 annual periods from 2002 to 2024. As of June 2025, the ratio stands at 19.6%, reflecting working capital of GBX501.00 Million against net assets of GBX2.55 Billion GBX. For the complete balance sheet picture, see HIK current and non-current assets.
Annual Working Capital to Net Assets for Hikma Pharmaceuticals PLC (2002–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Hikma Pharmaceuticals PLC from 2002 to 2024, covering 23 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check Hikma Pharmaceuticals PLC liquidity resilience to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (GBX) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 12.3% | GBX285.00 Million | GBX2.32 Billion | GBX2.26 Billion | GBX1.98 Billion | ▼ -22.2 pp |
| 2023 | 34.4% | GBX761.00 Million | GBX2.21 Billion | GBX2.10 Billion | GBX1.34 Billion | ▼ -8.5 pp |
| 2022 | 42.9% | GBX922.00 Million | GBX2.15 Billion | GBX2.00 Billion | GBX1.08 Billion | ▼ -0.8 pp |
| 2021 | 43.7% | GBX1.08 Billion | GBX2.47 Billion | GBX2.09 Billion | GBX1.02 Billion | ▲ +2.1 pp |
| 2020 | 41.6% | GBX894.00 Million | GBX2.15 Billion | GBX1.92 Billion | GBX1.03 Billion | ▲ +23.9 pp |
| 2019 | 17.7% | GBX377.00 Million | GBX2.13 Billion | GBX1.85 Billion | GBX1.47 Billion | ▼ -28.0 pp |
| 2018 | 45.7% | GBX775.00 Million | GBX1.70 Billion | GBX1.67 Billion | GBX893.00 Million | ▼ -5.2 pp |
| 2017 | 50.9% | GBX777.00 Million | GBX1.53 Billion | GBX1.57 Billion | GBX797.00 Million | ▲ +28.9 pp |
| 2016 | 22.0% | GBX530.00 Million | GBX2.41 Billion | GBX1.45 Billion | GBX918.00 Million | ▼ -34.8 pp |
| 2015 | 56.8% | GBX768.00 Million | GBX1.35 Billion | GBX1.36 Billion | GBX592.00 Million | ▲ +42.7 pp |
| 2014 | 14.1% | GBX172.00 Million | GBX1.22 Billion | GBX1.01 Billion | GBX841.00 Million | ▼ -15.9 pp |
| 2013 | 30.1% | GBX311.00 Million | GBX1.03 Billion | GBX897.00 Million | GBX586.00 Million | ▼ -7.1 pp |
| 2012 | 37.2% | GBX315.01 Million | GBX847.85 Million | GBX781.97 Million | GBX466.95 Million | ▲ +3.4 pp |
| 2011 | 33.7% | GBX269.30 Million | GBX798.63 Million | GBX659.88 Million | GBX390.58 Million | ▲ +3.7 pp |
| 2010 | 30.1% | GBX225.49 Million | GBX750.30 Million | GBX494.12 Million | GBX268.62 Million | ▼ -6.9 pp |
| 2009 | 36.9% | GBX252.16 Million | GBX683.26 Million | GBX456.60 Million | GBX204.44 Million | ▲ +6.2 pp |
| 2008 | 30.7% | GBX186.77 Million | GBX609.00 Million | GBX415.21 Million | GBX228.43 Million | ▲ +37.2 pp |
| 2007 | -6.6% | GBX-27.84 Million | GBX424.66 Million | GBX366.20 Million | GBX394.04 Million | ▼ -61.8 pp |
| 2006 | 55.2% | GBX193.11 Million | GBX349.80 Million | GBX299.83 Million | GBX106.73 Million | ▼ -17.2 pp |
| 2005 | 72.4% | GBX208.24 Million | GBX287.48 Million | GBX284.94 Million | GBX76.70 Million | ▲ +12.3 pp |
| 2004 | 60.1% | GBX87.24 Million | GBX145.18 Million | GBX160.48 Million | GBX73.23 Million | ▼ -9.9 pp |
| 2003 | 70.0% | GBX42.36 Million | GBX60.47 Million | GBX80.35 Million | GBX38.00 Million | ▲ +12.3 pp |
| 2002 | 57.8% | GBX27.74 Million | GBX48.03 Million | GBX64.37 Million | GBX36.63 Million | — |